AR114350A1 - Terapia genética para la distrofia muscular de cinturas del tipo 2c - Google Patents
Terapia genética para la distrofia muscular de cinturas del tipo 2cInfo
- Publication number
- AR114350A1 AR114350A1 ARP190100213A ARP190100213A AR114350A1 AR 114350 A1 AR114350 A1 AR 114350A1 AR P190100213 A ARP190100213 A AR P190100213A AR P190100213 A ARP190100213 A AR P190100213A AR 114350 A1 AR114350 A1 AR 114350A1
- Authority
- AR
- Argentina
- Prior art keywords
- type
- dystrophy
- muscular
- waist
- genetic therapy
- Prior art date
Links
- 230000002068 genetic effect Effects 0.000 title 1
- 230000003387 muscular Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 102100021792 Gamma-sarcoglycan Human genes 0.000 abstract 2
- 101000616435 Homo sapiens Gamma-sarcoglycan Proteins 0.000 abstract 2
- 238000001415 gene therapy Methods 0.000 abstract 2
- 201000006938 muscular dystrophy Diseases 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 239000013607 AAV vector Substances 0.000 abstract 1
- 108010083379 Sarcoglycans Proteins 0.000 abstract 1
- 102000006308 Sarcoglycans Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Vectores de terapia genética tales como vectores AAV. que comprenden un polinucleótido que codifica sarcoglicano (SGCG) y métodos para usar tales vectores de terapia genética para el tratamiento de sujetos que sufren de distrofia muscular, por ejemplo distrofia muscular de cinturas del tipo 2C (LGMD2C).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862624616P | 2018-01-31 | 2018-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR114350A1 true AR114350A1 (es) | 2020-08-26 |
Family
ID=67478478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190100213A AR114350A1 (es) | 2018-01-31 | 2019-01-30 | Terapia genética para la distrofia muscular de cinturas del tipo 2c |
Country Status (17)
Country | Link |
---|---|
US (1) | US20200360534A1 (es) |
EP (1) | EP3746100A4 (es) |
JP (2) | JP7361701B2 (es) |
KR (1) | KR20200115585A (es) |
CN (1) | CN111818946A (es) |
AR (1) | AR114350A1 (es) |
AU (1) | AU2019216257A1 (es) |
BR (1) | BR112020015173A2 (es) |
CA (1) | CA3089080A1 (es) |
CL (2) | CL2020001948A1 (es) |
CO (1) | CO2020010270A2 (es) |
EA (1) | EA202091739A1 (es) |
IL (1) | IL275880A (es) |
MX (1) | MX2020007876A (es) |
SG (1) | SG11202006722RA (es) |
TW (1) | TWI815856B (es) |
WO (1) | WO2019152474A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200115598A (ko) | 2018-01-30 | 2020-10-07 | 애프니메드, 인코포레이티드 (델라웨어) | 수면 무호흡증을 치료하기 위한 방법 및 조성물 |
EP4051324A4 (en) * | 2019-10-28 | 2023-11-29 | University Of Florida Research Foundation, Incorporated | GENE THERAPY VECTORS |
EP4117783A4 (en) * | 2019-12-16 | 2024-08-21 | Res Inst Nationwide Childrens Hospital | COMPOSITIONS AND METHODS FOR RESTORING AND MAINTAINING DYSTROPHIN-ASSOCIATED PROTEIN COMPLEX (DAPC) |
CN116348149A (zh) * | 2020-06-15 | 2023-06-27 | 全国儿童医院研究所 | 用于肌营养不良症的腺相关病毒载体递送 |
EP4168052A2 (en) | 2020-06-19 | 2023-04-26 | Genethon | Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg |
TW202227634A (zh) | 2020-09-08 | 2022-07-16 | 美商薩羅塔治療公司 | 表現γ—肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療 |
JP2023081369A (ja) * | 2021-11-30 | 2023-06-09 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用 |
EP4198134A1 (en) | 2021-12-16 | 2023-06-21 | Genethon | Gamma-sarcoglycan gene transfer increase using modified itr sequences |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262035B1 (en) * | 1998-10-01 | 2001-07-17 | University Of Iowa Research Foundation | Gene replacement therapy for muscular dystrophy |
US20100247495A1 (en) * | 2009-03-30 | 2010-09-30 | Tom Ichim | Treatment of Muscular Dystrophy |
DE18200782T1 (de) * | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
US9878056B2 (en) * | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
EP3452101A2 (en) * | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
-
2019
- 2019-01-30 BR BR112020015173-4A patent/BR112020015173A2/pt unknown
- 2019-01-30 EA EA202091739A patent/EA202091739A1/ru unknown
- 2019-01-30 CA CA3089080A patent/CA3089080A1/en active Pending
- 2019-01-30 SG SG11202006722RA patent/SG11202006722RA/en unknown
- 2019-01-30 MX MX2020007876A patent/MX2020007876A/es unknown
- 2019-01-30 US US16/966,407 patent/US20200360534A1/en active Pending
- 2019-01-30 JP JP2020540722A patent/JP7361701B2/ja active Active
- 2019-01-30 CN CN201980009966.2A patent/CN111818946A/zh active Pending
- 2019-01-30 KR KR1020207024618A patent/KR20200115585A/ko not_active Application Discontinuation
- 2019-01-30 AR ARP190100213A patent/AR114350A1/es unknown
- 2019-01-30 TW TW108103617A patent/TWI815856B/zh active
- 2019-01-30 AU AU2019216257A patent/AU2019216257A1/en active Pending
- 2019-01-30 EP EP19747125.3A patent/EP3746100A4/en active Pending
- 2019-01-30 WO PCT/US2019/015779 patent/WO2019152474A1/en active Application Filing
-
2020
- 2020-07-06 IL IL275880A patent/IL275880A/en unknown
- 2020-07-24 CL CL2020001948A patent/CL2020001948A1/es unknown
- 2020-08-31 CO CONC2020/0010270A patent/CO2020010270A2/es unknown
-
2021
- 2021-11-23 CL CL2021003097A patent/CL2021003097A1/es unknown
-
2023
- 2023-10-03 JP JP2023171950A patent/JP2023171900A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019152474A1 (en) | 2019-08-08 |
US20200360534A1 (en) | 2020-11-19 |
SG11202006722RA (en) | 2020-08-28 |
CL2021003097A1 (es) | 2022-07-15 |
JP2023171900A (ja) | 2023-12-05 |
EP3746100A4 (en) | 2021-11-17 |
JP2021512072A (ja) | 2021-05-13 |
KR20200115585A (ko) | 2020-10-07 |
CL2020001948A1 (es) | 2020-10-09 |
JP7361701B2 (ja) | 2023-10-16 |
TWI815856B (zh) | 2023-09-21 |
CA3089080A1 (en) | 2019-08-08 |
CN111818946A (zh) | 2020-10-23 |
TW201934751A (zh) | 2019-09-01 |
BR112020015173A2 (pt) | 2020-12-29 |
WO2019152474A9 (en) | 2020-08-27 |
MX2020007876A (es) | 2020-12-03 |
EP3746100A1 (en) | 2020-12-09 |
IL275880A (en) | 2020-08-31 |
EA202091739A1 (ru) | 2021-01-14 |
AU2019216257A1 (en) | 2020-07-23 |
CO2020010270A2 (es) | 2020-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR114350A1 (es) | Terapia genética para la distrofia muscular de cinturas del tipo 2c | |
CO2018012084A2 (es) | Administración de vectores del virus adenoasociado de microdistrofina para tratar la distrofia muscular | |
PH12018502645A1 (en) | Optimized mini-dystrophin genes and expression cassettes and their use | |
PH12018500964A1 (en) | Modified friedreich ataxia genes and vectors for gene therapy | |
SA519401435B1 (ar) | مركبات حلقية ثنائية النيوكليوتيد | |
CO2019011250A2 (es) | Administración de vectores del virus adenoasociado de microdistrofina específica del músculo para tratar la distrofia muscular | |
MX2020010694A (es) | Particulas de raav que codifican mir-708 y usos del mismo. | |
CL2020003289A1 (es) | Suministro en vector del virus adeno-asociado de micro-distrofina específica de músculos para tratar la distrofia muscular | |
MX2016001204A (es) | Vectores virales adeno-asociados (aav) utiles para transducir tejido adiposo. | |
MX2020005470A (es) | Composiciones y metodos para enfermedades neurologicas. | |
BR112017005235A2 (pt) | vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc) | |
CO2021012074A2 (es) | Suministro de β-sarcoglicano mediante vectores de virus adenoasociado y el tratamiento de la distrofia muscular | |
ZA201803080B (en) | Methods of treating muscular dystrophy | |
MX2021005435A (es) | Transgen abcb11 con codones optimizados para el tratamiento de colestasis intrahepatica familiar progresiva tipo 2 (pfic2). | |
NZ765719A (en) | Adeno-associated virus (aav) vector having hybrid hgf gene introduced thereto | |
MX2021014337A (es) | Vectores de genoterapia para osteopetrosis maligna infantil. | |
MX2015007650A (es) | Tratamiento de retinitis pigmentosa. | |
MX2019010599A (es) | Usos medicos para tratamiento de retinitis pigmentosa. | |
MA42736B1 (fr) | Méthodes de traitement de la dystrophie musculaire | |
EA201892338A1 (ru) | Доставка микродистрофина вектором на основе аденоассоциированного вируса для лечения мышечной дистрофии |